XML 12 R2.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2025
Sep. 30, 2024
Current Assets:    
Cash and cash equivalents $ 6,089,126 $ 3,251,880
Inventory 17,208,967 8,268,766
Prepaid expenses 1,313,176 2,700,000
Total Current Assets 24,611,269 14,220,646
Operating lease right-of-use asset, net 880,732 246,247
Deposits 38,062 38,062
In-process research and development 92,800,000 92,800,000
Goodwill 9,346,796 9,346,796
Total Other Assets 102,184,858 102,184,858
Total Assets 127,676,859 116,651,751
Current Liabilities:    
Accounts payable 10,094,042 4,927,211
License payable 28,400,000 28,400,000
Accrued expenses 8,523,675 17,027
Accrued compensation 3,710,041 2,229,018
Note payable 1,000,000
Operating lease liability 114,694 241,547
Total Current Liabilities 51,842,452 35,814,803
Deferred tax liability 7,506,520 6,713,800
Operating lease liability - noncurrent 766,957 21,318
Total Liabilities 60,115,929 42,549,921
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - $0.001 par value; 250,000,000 and 16,000,000 shares authorized; 14,475,029 and 7,247,243 shares issued and outstanding at June 30, 2025 and September 30, 2024, respectively 14,475 7,247
Additional paid-in capital 295,888,916 271,440,421
Accumulated deficit (230,844,841) (201,370,218)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 65,058,550 70,077,450
Non-controlling interest 2,502,380 4,024,380
Total Equity 67,560,930 74,101,830
Total Liabilities and Equity $ 127,676,859 $ 116,651,751